Search Results

Nordic Nanovector - Completion of annual general meeting

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA on 6 June 2023 regarding the Company’s acquisition of Thor Medical AS, with approval of the Transaction from the Company’s annual general meeting as one of the closing conditions.

June 28, 2023

·

1 min read

Business

Nordic Nanovector - Appointment of Alf Bjørseth as CEO

Reference is made to the stock exchange announcement made earlier by Nordic Nanovector ASA, where the Company announced, among other things, that the annual general meeting had elected new board members to the board of directors, including electing former interim CFO & CEO Ludvik Sandnes as new chairman.

June 28, 2023

·

1 min read

Nordic Nanovector - Annual and Remuneration Reports Approved

On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022.

March 23, 2023

·

1 min read

Nordic Nanovector - Notice of Annual General Meeting on 28 June 2023

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 June 2023, at 14:00 hours CEST at Advokatfirmaet CLP, Sommerrogata 13-15, 0255 Oslo.

June 7, 2023

·

1 min read

Nordic Nanovector - Annual General Meeting Postponed

The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.

March 31, 2023

·

1 min read

Business

Nordic Nanovector ASA Results for the Second Half and Full Year 2022

Nordic Nanovector ASA announces its results for the second half and full year 2022. A presentation by Nordic Nanovector’s interim CEO & CFO, Ludvik Sandnes will be held in-person in Oslo and webcast live beginning at 8:30am CET - details below.

February 28, 2023

·

8 min read

Deals

Nordic Nanovector announces agreement to acquire Thor Medical, an emerging producer of alpha-emitters for radiopharmaceuticals to treat cancer

Nordic Nanovector ASA and Thor Medical AS, a privately held company focused on the production of alpha-emitting radionuclides for cancer treatment, announce that they have entered into a definitive share exchange agreement to combine the two companies in an all-share transaction.

June 6, 2023

·

10 min read

Pictured: Syringe drawing vaccine from a vial

Drug Development

Bavarian Nordic’s Mpox Vaccine Safe, Effective at Lower Doses: Study

A one-fifth dose of Bavarian Nordic’s mpox vaccine Jynneos can elicit a similar antibody response as its standard-dose regimen, according to findings presented Saturday at the European Society of Clinical Microbiology and Infectious Diseases Global Congress.

April 29, 2024

·

2 min read

·

Tristan Manalac

Bavarian Nordic's sign outside its facility in Germany

Vaccines

Bavarian Nordic’s Jynneos Elicits ‘Robust’ Mpox Antibody Response in Adolescents: Study

The mpox vaccine induced an antibody response in adolescents aged 12 to 17 years that matched that in adults, suggesting the shot can be used to protect the highly susceptible group.

October 17, 2024

·

2 min read

·

Tristan Manalac

Press Releases

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine

October 29, 2024

·

4 min read